| Cas Number: | 57010-31-8 |
| Pubchem: | 42107 |
| Chemspiderid: | 38399 |
| Unii: | 0ONY823T4J |
| Smiles: | CN(CCCC1(S(=O)(=O)CCCS1(=O)=O)C2=CC(=C(C=C2)OC)OC)CCC3=CC(=C(C=C3)OC)OC |
| Synonyms: | Dimeditiapramine; Ro 11-1781 |
| Iupac Name: | 2-(3,4-Dimethoxyphenyl)-2-(3- |
| C: | 26 |
| H: | 37 |
| N: | 1 |
| O: | 8 |
| S: | 2 |
Tiapamil (INN; also known as dimeditiapramine) is a calcium antagonist or calcium channel blocker.[1] [2] It is an experimental drug that has never been marketed.[3]
Tiapamil has been described as an antianginal agent. It exhibits properties of anti-arrhythmic medications. These are medications that are used to treat unusually fast or irregular heartbeats. Examples of arrhytmthic conditions include atrial fibrillation, atrial flutter, and super-ventricular tachycardia.[4] Upon research, the drug shows promising effects on treatment of these condition. Research seeks to create a treatment with tiapamil in order to mitigate the side effects of the more commonly prescribed calcium antagonist and anti-hypertensive verapamil. The two drugs have similar properties; however, tiapamil appears to treat arrhythmic conditions without many of the hypotensive, negative inotropic, and negative chronotropic side effects. Tiapamil is a calcium channel blocker that acts on the slow calcium channels. It can treat ventricular arrhythmias to a higher degree than traditional calcium antagonists.